Zelira Therapeutics Limited (ASX:ZLD)

Market Cap	5.95M -16.8%
Revenue (ttm)	656.00 -99.3%
Net Income	-3.63M
EPS	-0.32
Shares Out	11.90M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19,140
Average Volume	10,153
Open	0.5000
Previous Close	0.5000
Day's Range	0.4850 - 0.5000
52-Week Range	0.3100 - 1.1500
Beta	0.56
RSI	39.87
Earnings Date	May 26, 2026

About Zelira Therapeutics

Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops ZENIVOL, a cannabinoid drug for the treatment of chronic insomnia. The company also provides over the counter (OTC) products, including SprinJeneCBD, an oral care product; and acne treatment product...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ZLD

Financial Performance

In fiscal year 2025, Zelira Therapeutics's revenue was 656, a decrease of -99.31% compared to the previous year's 94,952. Losses were -3.63 million, -90.08% less than in 2024.